May 2004
Volume 45, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2004
Primary intravitreal triamcinolone acetonide for severe diabetic hard exudates: a clinical and fluorescein angiographic study
Author Affiliations & Notes
  • A. Ladjimi
    Ophthalmology, Fattouma Bourguiba University Hospital, Monastir, Tunisia
  • S. Zaouali
    Ophthalmology, Fattouma Bourguiba University Hospital, Monastir, Tunisia
  • S. Jenzeri
    Ophthalmology, Fattouma Bourguiba University Hospital, Monastir, Tunisia
  • R. Messaoud
    Ophthalmology, Fattouma Bourguiba University Hospital, Monastir, Tunisia
  • H. Mzali
    Ophthalmology, Fattouma Bourguiba University Hospital, Monastir, Tunisia
  • M. Khairallah
    Ophthalmology, Fattouma Bourguiba University Hospital, Monastir, Tunisia
  • Footnotes
    Commercial Relationships  A. Ladjimi, None; S. Zaouali, None; S. Jenzeri, None; R. Messaoud, None; H. Mzali, None; M. Khairallah, None.
  • Footnotes
    Support  none
Investigative Ophthalmology & Visual Science May 2004, Vol.45, 4068. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      A. Ladjimi, S. Zaouali, S. Jenzeri, R. Messaoud, H. Mzali, M. Khairallah; Primary intravitreal triamcinolone acetonide for severe diabetic hard exudates: a clinical and fluorescein angiographic study . Invest. Ophthalmol. Vis. Sci. 2004;45(13):4068.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: To analyze the clinical and angiographic outcomes of diabetic macular edema with severe hard exudates treated with intravitreal triamcinolone acetonide (TA). Methods: The study included 12 eyes of 12 patients with severe diabetic macular hard exudates, who received an intravitreal injection of 4 mg of TA. Mean + SD age was 58.07 + 10.28 years. Evaluation before injection and throughout follow–up included Snellen visual acuity, slit–lamp examination, fundus photography, and fluorescein angiography. Follow–up period ranged from 3 to 12 months (mean, 6.27 months). Results: Mean visual acuity improved significantly from 20/300 to 20/160 (p = 0.039). Hard exudates resolved completely in 4 eyes (33%) and partially in 8 eyes (66%). Fluorescein leakage decreased significantly in 11 eyes (91.7%). A decrease in microaneurysms number was observed in all cases. An intraocular pressure elevation occurred in 3 eyes (25%), and was successfully treated by topical medication. No other complications, such as endophthalmitis or pseudo–endophthalmitis were recorded. Conclusions: Intravitreal injection of TA appears to be beneficial for reducing hard exudates, decreasing fluorescein leakage, reducing the number of microaneurysms and improving significantly visual acuity in patients with severe diabetic hard exudates. Further studies with a larger number of patients are required to assess the long–term efficacy and safety, and the need for retreatment.

Keywords: corticosteroids • imaging methods (CT, FA, ICG, MRI, OCT, RTA, SLO, ultrasound) • macula/fovea 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×